These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 21228029

  • 41. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 42. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J, Sittl R.
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [Abstract] [Full Text] [Related]

  • 43. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED.
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [Abstract] [Full Text] [Related]

  • 44. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 45. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E.
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [Abstract] [Full Text] [Related]

  • 46. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP.
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [Abstract] [Full Text] [Related]

  • 47. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [Abstract] [Full Text] [Related]

  • 48. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 49. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L, Iut VC, Etchepare A, D'Eramo M, Grinspan A, Assefi A.
    Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
    [Abstract] [Full Text] [Related]

  • 50. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 51. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P.
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [Abstract] [Full Text] [Related]

  • 52. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K, Sipe JC.
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [Abstract] [Full Text] [Related]

  • 53. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.
    Mult Scler; 2018 Feb; 24(2):222-226. PubMed ID: 28140753
    [Abstract] [Full Text] [Related]

  • 54. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 55. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 Dec; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 56. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 57. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R.
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [Abstract] [Full Text] [Related]

  • 59. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E.
    Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
    [Abstract] [Full Text] [Related]

  • 60. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A.
    Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.